PL2004155T3 - Inhibitory agregacji białek - Google Patents
Inhibitory agregacji białekInfo
- Publication number
- PL2004155T3 PL2004155T3 PL07712961T PL07712961T PL2004155T3 PL 2004155 T3 PL2004155 T3 PL 2004155T3 PL 07712961 T PL07712961 T PL 07712961T PL 07712961 T PL07712961 T PL 07712961T PL 2004155 T3 PL2004155 T3 PL 2004155T3
- Authority
- PL
- Poland
- Prior art keywords
- inhibitors
- protein aggregation
- aggregation
- protein
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 230000004845 protein aggregation Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
- C07D279/20—[b, e]-condensed with two six-membered rings with hydrogen atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/003—Thiazine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0465—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Optics & Photonics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78670006P | 2006-03-29 | 2006-03-29 | |
EP07712961.7A EP2004155B1 (en) | 2006-03-29 | 2007-03-28 | Inhibitors of protein aggregation |
PCT/GB2007/001105 WO2007110629A1 (en) | 2006-03-29 | 2007-03-28 | Inhibitors of protein aggregation |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2004155T3 true PL2004155T3 (pl) | 2018-08-31 |
Family
ID=38068838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL07712961T PL2004155T3 (pl) | 2006-03-29 | 2007-03-28 | Inhibitory agregacji białek |
Country Status (13)
Country | Link |
---|---|
US (3) | US8263589B2 (pl) |
EP (1) | EP2004155B1 (pl) |
JP (1) | JP5654748B2 (pl) |
CN (2) | CN101460157B (pl) |
AU (1) | AU2007231126B2 (pl) |
CA (1) | CA2645946C (pl) |
DK (1) | DK2004155T3 (pl) |
ES (1) | ES2667002T3 (pl) |
MY (1) | MY153198A (pl) |
PL (1) | PL2004155T3 (pl) |
PT (1) | PT2004155T (pl) |
SI (1) | SI2004155T1 (pl) |
WO (1) | WO2007110629A1 (pl) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5186212B2 (ja) | 2004-09-23 | 2013-04-17 | ウィスタ ラボラトリーズ リミテッド | メチルチオニニウム塩化物(mtc)などのジアミノフェノチアジニウム化合物を化学合成および精製する方法 |
AU2007231124B2 (en) | 2006-03-29 | 2013-02-21 | Wista Laboratories Ltd. | 3,7-diamino-10H-phenothiazine salts and their use |
CA2645946C (en) | 2006-03-29 | 2014-04-01 | Wista Laboratories Ltd. | Inhibitors of protein aggregation |
FR2903696B1 (fr) | 2006-07-12 | 2011-02-11 | Provence Technologies | Procede de purification de composes diaminophenothiazium |
SI2167095T1 (sl) * | 2007-06-19 | 2019-09-30 | Wista Laboratories Ltd. | Fenotiazinske spojine za zdravljenje blage kognitivne motnje |
PT2205245E (pt) * | 2007-10-03 | 2015-10-13 | Wista Lab Ltd | Utilização terapêutica de diaminofenotiazinas |
SI3792254T1 (sl) * | 2009-09-24 | 2023-11-30 | Wista Laboratories Ltd. | Kristalinični hidrati metiltioninijevega klorida |
AU2016202982B2 (en) * | 2009-09-24 | 2017-09-21 | Wista Laboratories Ltd | Crystalline methylthionium chloride (methylene blue) hydrates |
US8785434B2 (en) | 2010-04-30 | 2014-07-22 | Prosetta Antiviral Inc. | Antiviral compounds |
US8828986B2 (en) | 2011-04-20 | 2014-09-09 | Prosetta Antiviral Inc. | Antiviral compounds |
CA2826286C (en) | 2011-01-31 | 2021-09-21 | Intellect Neurosciences Inc. | Treatment of tauopathies |
CA2827027C (en) | 2011-02-11 | 2019-06-04 | Wista Laboratories Ltd. | Phenothiazine diaminium salts and their use |
CN102690244A (zh) * | 2011-03-22 | 2012-09-26 | 中国科学院上海生命科学研究院 | 调节α-突触核蛋白积聚的物质及其制药用途 |
GB201317702D0 (en) * | 2013-10-07 | 2013-11-20 | Wista Lab Ltd | Methods of chemical synthesis of diaminophenothiazinium compounds including methylthioninium chloride (MTC) |
EP3207925A1 (en) * | 2016-02-22 | 2017-08-23 | Universität Wien | Compound for use in the prevention and treatment of neurodegenerative diseases |
PT3383381T (pt) * | 2015-11-30 | 2020-07-03 | Universita¿T Wien | Composto para uso na prevenção e tratamento de doenças neurodegenerativas |
CN106046027B (zh) * | 2016-06-30 | 2019-03-05 | 广东工业大学 | 一种含吡咯并吩噻嗪-1,3-二酮衍生物及其制备方法与应用 |
AU2017301966B2 (en) | 2016-07-25 | 2022-09-22 | Wista Laboratories Ltd. | Administration and dosage of diaminophenothiazines |
WO2018158160A1 (en) | 2017-02-28 | 2018-09-07 | Universitat Autonoma De Barcelona | (nitro-phenyl)-nitropyridine compounds for treating synucleinopathies |
FR3063495B1 (fr) * | 2017-03-02 | 2019-04-05 | Provepharm Life Solutions | Procede de preparation de l’iodure de 3,7-bis(dimethylamino)phenothiazine-5-ylium |
US11358942B2 (en) | 2017-06-05 | 2022-06-14 | Board Of Trustees Of Michigan State University | Substituted phenothiazines as proteasome activators |
WO2019025424A1 (en) | 2017-08-04 | 2019-02-07 | Universitat Autonoma De Barcelona | COMPOUNDS FOR TREATING SYNUCLEINOPATHIES |
WO2019161917A1 (en) | 2018-02-23 | 2019-08-29 | Universitat Autonoma De Barcelona | 4-substituted 1-ethenylsulfonyl-2-nitrobenzene compounds for treating synucleinopathies |
EP4385512A1 (en) | 2018-07-26 | 2024-06-19 | WisTa Laboratories Ltd. | Optimised dosage of diaminophenothiazines in populations |
US11155609B2 (en) | 2019-04-05 | 2021-10-26 | TauC3 Biologies Limited | Anti-TAUC3 antibodies and uses thereof |
EP3952745A1 (en) * | 2019-04-10 | 2022-02-16 | Genting Taurx Diagnostic Centre SDN BHD | Adaptive neurological testing method |
JP2023502794A (ja) * | 2019-11-19 | 2023-01-25 | モダグ ゲーエムベーハー | α-シヌクレインの凝集に関連する疾患の診断、治療および予防のための新規な化合物 |
WO2023232764A1 (en) | 2022-05-31 | 2023-12-07 | Wista Laboratories Ltd. | Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE569430A (pl) * | 1957-07-17 | |||
US4309255A (en) * | 1980-09-10 | 1982-01-05 | International Business Machines Corporation | Electrochromic recording paper |
US4647525A (en) * | 1984-10-01 | 1987-03-03 | Minnesota Mining And Manufacturing Company | Stabilized leuco phenazine dyes and their use in an imaging system |
US4622395A (en) * | 1984-10-01 | 1986-11-11 | Minnesota Mining And Manufacturing Company | Phenoxazine and phenothiazine dyes and leuco forms thereof |
GB8724412D0 (en) | 1987-10-19 | 1987-11-25 | Medical Res Council | Protein |
US5571666A (en) * | 1988-10-28 | 1996-11-05 | Oklahoma Medical Research Foundation | Thiazine dyes used to inactivate HIV in biological fluids |
US5220009A (en) * | 1990-05-03 | 1993-06-15 | Yeda Research And Development Company Limited | Phenothiazinium salts and their use for disinfecting aqueous effluents |
JPH0725786A (ja) | 1990-05-16 | 1995-01-27 | Univ Rockefeller | アルツハイマー病を伴うアミロイドーシスの治療 |
EP0600951A4 (en) | 1991-08-01 | 1996-10-30 | Paul H Voorheis | Diagnostic method for alzheimer's disease. |
WO1993003177A1 (en) | 1991-08-09 | 1993-02-18 | Massachusetts Institute Of Technology | Novel tau/neurofilament protein kinases |
WO1993011231A1 (en) | 1991-12-06 | 1993-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Tools for the diagnosis and treatment of alzheimer's disease |
JPH06289015A (ja) | 1993-03-30 | 1994-10-18 | Sunstar Inc | フェノチアジン系色源体安定化組成物 |
GB9316727D0 (en) | 1993-08-12 | 1993-09-29 | Inst Of Psychiatry | Models of alzheimers's disease |
GB9317193D0 (en) | 1993-08-18 | 1993-10-06 | Zeneca Ltd | Method |
EP0778773A1 (en) | 1994-08-08 | 1997-06-18 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes |
DE4430091A1 (de) | 1994-08-25 | 1996-02-29 | Bayer Ag | Verwendung von N-substituierten Phenothiazinen |
GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
US5804601A (en) | 1995-04-10 | 1998-09-08 | Takeda Chemical Industries, Ltd. | Aromatic hydroxamic acid compounds, their production and use |
US5693638A (en) * | 1996-02-23 | 1997-12-02 | Myers; Daniel | Method of treating a migraine headache |
US6333322B1 (en) * | 1996-03-13 | 2001-12-25 | Eisai Co., Ltd. | Nitrogen-containing tricyclic compounds and drugs containing the same |
AU4322999A (en) | 1998-06-01 | 1999-12-20 | Advanced Research And Technology Institute, Inc. | Methods and compositions for diagnosing tauopathies |
FR2788436A1 (fr) | 1999-01-14 | 2000-07-21 | Pf Medicament | Composition d'un derive de phenothiazine |
EP1248518A2 (en) | 2000-01-21 | 2002-10-16 | PHARMACIA & UPJOHN COMPANY | Transgenic mouse model of human neurodegenerative disease |
GB0017060D0 (en) * | 2000-07-11 | 2000-08-30 | Hunter Fleming Ltd | Production, stabilisation and use of reduced forms of pharmaceutical compounds |
GB0100119D0 (en) | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
GB0101049D0 (en) * | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
NZ528322A (en) * | 2001-03-15 | 2005-03-24 | Proteotech Inc | Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases such as alzheimer's disease and parkinson's |
GB0106953D0 (en) * | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
US20020197258A1 (en) * | 2001-06-22 | 2002-12-26 | Ghanbari Hossein A. | Compositions and methods for preventing protein aggregation in neurodegenerative diseases |
GB0117326D0 (en) | 2001-07-16 | 2001-09-05 | Univ Aberdeen | Napthoquinone-type inhibitors of protein aggregation |
US20030217370A1 (en) | 2002-05-16 | 2003-11-20 | Giasson Benoit I. | Transgenic animal expressing alpha-synuclein and uses thereof |
JP3867639B2 (ja) * | 2002-07-31 | 2007-01-10 | 株式会社デンソー | 混成集積回路装置 |
US6953974B2 (en) | 2003-08-26 | 2005-10-11 | Texas Instruments Incorporated | EEPROM device and method for providing lower programming voltage |
GB0322756D0 (en) | 2003-09-29 | 2003-10-29 | Univ Aberdeen | Methods of chemical synthesis |
KR20060111536A (ko) | 2003-11-28 | 2006-10-27 | 포토파미카 리미티드 | 생물학적 활성 메틸렌 블루 유도체(2)의 개발 |
ATE442588T1 (de) * | 2004-03-31 | 2009-09-15 | Anges Mg Inc | Testverfahren zur identifizierung eines kandidatenarzneistoffs |
GB0420963D0 (en) | 2004-09-21 | 2004-10-20 | Reneuron Ltd | Hepatocyte |
SI1799662T1 (sl) | 2004-09-23 | 2013-08-30 | Wista Laboratories Ltd. | Postopki za kemijsko sintezo in čiščenje diaminofenotiazinijevih spojin, vključno metiltioninijevega klorida (MTC) |
JP5186212B2 (ja) * | 2004-09-23 | 2013-04-17 | ウィスタ ラボラトリーズ リミテッド | メチルチオニニウム塩化物(mtc)などのジアミノフェノチアジニウム化合物を化学合成および精製する方法 |
DE112006002052A5 (de) | 2005-05-18 | 2008-05-08 | Forschungsverbund Berlin E.V. | Nicht-Peptidische Inhibitoren der AKAP-PKA-Wechselwirkung |
WO2007056439A1 (en) * | 2005-11-08 | 2007-05-18 | Collegium Pharmaceutical, Inc. | Salts of methylene blue and its derivatives |
CA2645946C (en) | 2006-03-29 | 2014-04-01 | Wista Laboratories Ltd. | Inhibitors of protein aggregation |
AU2007231124B2 (en) | 2006-03-29 | 2013-02-21 | Wista Laboratories Ltd. | 3,7-diamino-10H-phenothiazine salts and their use |
-
2007
- 2007-03-28 CA CA2645946A patent/CA2645946C/en active Active
- 2007-03-28 SI SI200732019T patent/SI2004155T1/en unknown
- 2007-03-28 CN CN200780020257.1A patent/CN101460157B/zh active Active
- 2007-03-28 US US12/294,605 patent/US8263589B2/en active Active
- 2007-03-28 ES ES07712961.7T patent/ES2667002T3/es active Active
- 2007-03-28 PL PL07712961T patent/PL2004155T3/pl unknown
- 2007-03-28 EP EP07712961.7A patent/EP2004155B1/en active Active
- 2007-03-28 MY MYPI20083823A patent/MY153198A/en unknown
- 2007-03-28 CN CN201310556670.7A patent/CN103735554B/zh active Active
- 2007-03-28 PT PT77129617T patent/PT2004155T/pt unknown
- 2007-03-28 AU AU2007231126A patent/AU2007231126B2/en active Active
- 2007-03-28 WO PCT/GB2007/001105 patent/WO2007110629A1/en active Application Filing
- 2007-03-28 JP JP2009502206A patent/JP5654748B2/ja active Active
- 2007-03-28 DK DK07712961.7T patent/DK2004155T3/en active
-
2011
- 2011-01-21 US US13/011,797 patent/US8710051B2/en active Active
-
2014
- 2014-04-09 US US14/248,730 patent/US9174954B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US9174954B2 (en) | 2015-11-03 |
CN103735554B (zh) | 2018-03-20 |
WO2007110629A1 (en) | 2007-10-04 |
CA2645946C (en) | 2014-04-01 |
US20090209526A1 (en) | 2009-08-20 |
PT2004155T (pt) | 2018-05-02 |
EP2004155B1 (en) | 2018-02-21 |
AU2007231126A1 (en) | 2007-10-04 |
AU2007231126B2 (en) | 2012-11-01 |
CN101460157B (zh) | 2015-09-02 |
MY153198A (en) | 2015-01-29 |
DK2004155T3 (en) | 2018-04-30 |
US8263589B2 (en) | 2012-09-11 |
JP5654748B2 (ja) | 2015-01-14 |
ES2667002T3 (es) | 2018-05-09 |
SI2004155T1 (en) | 2018-05-31 |
CA2645946A1 (en) | 2007-10-04 |
US20110118242A1 (en) | 2011-05-19 |
CN101460157A (zh) | 2009-06-17 |
EP2004155A1 (en) | 2008-12-24 |
US8710051B2 (en) | 2014-04-29 |
JP2009531404A (ja) | 2009-09-03 |
US20140221359A1 (en) | 2014-08-07 |
CN103735554A (zh) | 2014-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2004155T3 (pl) | Inhibitory agregacji białek | |
HUS1900014I1 (hu) | Proteinkináz inhibitorok | |
IL198487A0 (en) | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors | |
HK1129298A1 (en) | Dihydrodiazepines useful as inhibitors of protein kinases | |
IL194123A0 (en) | Methods for reducing protein aggregation | |
IL198398A0 (en) | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors | |
EP2144875A4 (en) | PROTEIN INHIBITORS FLAP (5-LIPOXYGENASE-ACTIVATING PROTEIN) | |
EP2144874A4 (en) | INHIBITORS OF 5-LIPOXYGENASE ACTIVATION PROTEIN (FLAP) | |
IL194699A0 (en) | Tetrahydropteridines useful as inhibitors of protein kinases | |
IL208719A0 (en) | Inhibitors of protein kinases | |
EP2026843A4 (en) | THERAPEUTIC USES OF RTP801L INHIBITORS | |
IL206416A0 (en) | Benzofuropyrimidinones as protein kinase inhibitors | |
IL190292A0 (en) | PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka | |
EP2007383A4 (en) | INHIBITORS OF PROTEIN PRENYLTRANSFERASES | |
IL210073A0 (en) | Protein kinase inhibitors | |
EP2148859A4 (en) | PROTEIN INHIBITORS FLAP (5-LIPOXYGENASE-ACTIVATING PROTEIN) | |
EP2054056A4 (en) | SMALL MOLECULAR INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | |
EP2387572A4 (en) | PROTEIN KINASE C HEMMER AND ITS USE | |
IL210069A0 (en) | Protein kinase inhibitors | |
IL196307A0 (en) | Inhibition of alpha-synuclein aggregation | |
EP2054397A4 (en) | SMALL MOLECULAR HEMERS OF KYNURENINE-3-MONOXYGENASE | |
ZA200806871B (en) | Dihydrodiazepines useful as inhibitors of protein kinases | |
IL207415A0 (en) | Protein kinase inhibitors and use thereof | |
ZA201003420B (en) | Protein kinase inhibitors and use thereof | |
ZA201008214B (en) | 5-lipoxygenase-activating protein inhibitor |